Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of IMG-004 in Healthy Participants
NCT05349097Phase 1Completed
- Start
- Aug 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of img-004 in chronic spontaneous urticaria (CSU), rheumatoid arthritis (RA) and hidradenitis suppurativa (HS) (11 arms). Primary endpoint: Safety of IMG-004 at Day 24. Started Aug 2022; status: completed.
02
Drugs
img-004
03
Conditions
chronic spontaneous urticaria (CSU)rheumatoid arthritis (RA)hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05349097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349097.